Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
Theranexus takes Alzheimer’s drug combo into clinic
While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid
Latest news
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and more
Preclinical data suggest this could lead to treatments for diseases including lysosomal storage disorders, liver and muscle diseases, inflammatory disorders and neurodegeneration.
-
Axovant joins ever-growing Alzheimer’s failure club
have no effect on the underlying neurodegeneration in the disease.
-
Celgene pays $300m upfront for immunology start-up Delinia
The Delinia acquisition comes in the wake of other bolt-on deals most recently its takeover earlier this month of another immunology specialist - Anokion - and its December purchase of oncology, neurodegeneration
-
Lilly streamlines and culls leadership roles
Shaw will lead the division's focus on immunology, neurodegeneration and pain, as well as a number of the firm's already established treatments. ... Ricks added: "With new medicines recently launched - and potential new medicines in development for cancer
-
Lundbeck trial failure dashes hopes in Alzheimer's once again
the underlying neurodegeneration in Alzheimer's.
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination… it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
-
Pharma deals in September 2015
Gencia is also at the discovery phase in mitochondrial therapies in neurodegeneration, cardiovascular disease and other areas.
-
Pharma deals during February 2014
adolescence, and ultimately neurodegeneration due to the formation of fatty yellow nodules (xanthomas) in the brain.
-
Interview: Mike Hutton, Lilly
influence driving the neurodegeneration seen in the disease. ... of molecules throughout the cell – leading to neurodegeneration. “
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Featured jobs
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director - Digital
-
Great salary and benefits
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Scientific Team Lead
-
Competitive Salary
- Account Manager, Healthcare Advertising
-
Salary TBC
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
Account Director
-
Negotiable
- Director Healthcare PR Communications
-
Salary TBC
- Account Director – Global Healthcare PR
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Associate Medical Director
-
Salary TBC
-
Associate Medical Director
-
Highly Competitive
Subscribe to our email news alerts
- Hancock's 'Tech Revolution' for NHS to be limited by budgets
- Merck & Co picks Nike exec to be digital transformation leader
- Gilead and Aelix join forces to pursue HIV ‘cure’
- Roche preps new Kadcyla filings after phase 3 trial win
- Novartis buys cancer specialist Endocyte for $2.1bn
- Porterhouse Medical rewards superb client service skills
PMHub
Conversis
Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
